Zimmer Current Deferred Revenue vs Net Tangible Assets Analysis
ZBH Stock | USD 121.44 0.59 0.49% |
Zimmer Biomet financial indicator trend analysis is more than just analyzing Zimmer Biomet Holdings current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zimmer Biomet Holdings is a good investment. Please check the relationship between Zimmer Biomet Current Deferred Revenue and its Net Tangible Assets accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Current Deferred Revenue vs Net Tangible Assets
Current Deferred Revenue vs Net Tangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zimmer Biomet Holdings Current Deferred Revenue account and Net Tangible Assets. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Zimmer Biomet's Current Deferred Revenue and Net Tangible Assets is 0.15. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Zimmer Biomet Holdings, assuming nothing else is changed. The correlation between historical values of Zimmer Biomet's Current Deferred Revenue and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Zimmer Biomet Holdings are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Current Deferred Revenue i.e., Zimmer Biomet's Current Deferred Revenue and Net Tangible Assets go up and down completely randomly.
Correlation Coefficient | 0.15 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most indicators from Zimmer Biomet's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zimmer Biomet Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. As of now, Zimmer Biomet's Tax Provision is increasing as compared to previous years. The Zimmer Biomet's current Enterprise Value Over EBITDA is estimated to increase to 15.42, while Selling General Administrative is projected to decrease to under 2 B.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 4.9B | 4.9B | 4.7B | 3.6B | Total Revenue | 6.8B | 6.9B | 7.4B | 5.0B |
Zimmer Biomet fundamental ratios Correlations
Click cells to compare fundamentals
Zimmer Biomet Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zimmer Biomet fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 206.7M | 207M | 210.4M | 210.3M | 209.7M | 164.9M | |
Total Assets | 24.6B | 24.4B | 23.5B | 21.1B | 21.5B | 13.7B | |
Other Current Liab | 1.9B | 1.6B | 511M | 985M | 1.3B | 941.7M | |
Total Current Liabilities | 3.4B | 2.6B | 3.5B | 2.4B | 2.9B | 1.5B | |
Total Stockholder Equity | 12.4B | 12.2B | 12.7B | 12.0B | 12.5B | 7.4B | |
Property Plant And Equipment Net | 2.1B | 2.0B | 1.8B | 1.9B | 2.3B | 1.4B | |
Accounts Payable | 400.9M | 330M | 306.5M | 354.1M | 379.8M | 228.6M | |
Non Current Assets Total | 19.9B | 19.3B | 18.6B | 16.6B | 16.9B | 10.3B | |
Non Currrent Assets Other | 980.1M | 969.4M | 2.3B | 630.8M | 559.1M | 561.5M | |
Net Receivables | 1.4B | 1.5B | 1.3B | 1.4B | 1.4B | 975.8M | |
Liabilities And Stockholders Equity | 24.6B | 24.4B | 23.5B | 21.1B | 21.5B | 13.7B | |
Non Current Liabilities Total | 8.8B | 9.7B | 7.3B | 6.7B | 6.2B | 4.8B | |
Inventory | 2.4B | 2.5B | 2.1B | 2.1B | 2.4B | 1.4B | |
Other Current Assets | 357.1M | 377.8M | 607.1M | 522.9M | 366.1M | 363.9M | |
Other Stockholder Equity | 2.2B | 2.4B | 2.6B | 2.6B | 2.3B | 2.4B | |
Total Liab | 12.2B | 12.2B | 10.8B | 9.0B | 9.0B | 6.3B | |
Property Plant And Equipment Gross | 2.1B | 2.0B | 6.1B | 6.5B | 6.8B | 7.1B | |
Total Current Assets | 4.7B | 5.1B | 4.9B | 4.4B | 4.6B | 3.4B | |
Accumulated Other Comprehensive Income | (241.9M) | (297.8M) | (231.6M) | (179.3M) | (191M) | (181.5M) | |
Other Liab | 1.9B | 2.0B | 1.9B | 1.1B | 1.3B | 1.2B | |
Other Assets | 652.9M | 969.4M | 1.1B | 1.1B | 1.3B | 1.4B | |
Property Plant Equipment | 2.1B | 2.0B | 2.0B | 1.9B | 2.2B | 1.4B | |
Short Long Term Debt Total | 8.2B | 8.1B | 7.1B | 5.7B | 6.0B | 4.3B | |
Net Debt | 7.6B | 7.3B | 6.7B | 5.3B | 5.6B | 3.7B | |
Retained Earnings | 10.4B | 10.1B | 10.3B | 9.6B | 10.4B | 6.8B | |
Cash | 617.9M | 802.1M | 378.1M | 375.7M | 415.8M | 591.2M | |
Long Term Debt | 6.7B | 7.6B | 5.5B | 5.2B | 5.0B | 4.0B | |
Cash And Short Term Investments | 617.9M | 802.1M | 378.1M | 375.7M | 415.8M | 732.9M | |
Good Will | 9.6B | 9.3B | 8.9B | 8.6B | 8.8B | 6.0B | |
Intangible Assets | 7.3B | 7.1B | 5.5B | 5.1B | 4.9B | 4.2B | |
Treasury Stock | (6.7B) | (6.7B) | (6.7B) | (6.9B) | (6.2B) | (6.5B) | |
Net Tangible Assets | (4.5B) | (4.1B) | (2.8B) | (1.6B) | (1.5B) | (1.5B) | |
Noncontrolling Interest In Consolidated Entity | 4.7M | 5.2M | 5.7M | 6.7M | 6.0M | 5.7M | |
Retained Earnings Total Equity | 10.4B | 10.1B | 10.3B | 9.6B | 11.0B | 9.1B | |
Capital Surpluse | 8.9B | 9.1B | 9.3B | 9.5B | 10.9B | 7.5B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Zimmer Biomet Holdings information on this page should be used as a complementary analysis to other Zimmer Biomet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Zimmer Stock analysis
When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Zimmer Biomet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.24) | Dividend Share 0.96 | Earnings Share 4.6 | Revenue Per Share 35.889 | Quarterly Revenue Growth 0.032 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.